Eris Lifesciences has received approval for acquisition of 30% of the total share capital of Swiss Parenterals, a subsidiary of the company. With the objective of fully consolidating its position, enhancing operational synergy, and strengthening its long-term strategic presence, the company now proposes to acquire 100% ownership of Swiss. This consolidation is expected to provide complete managerial control, enable full financial consolidation, improve cost efficiencies, streamline governance, and contribute to enhanced shareholder value.
The proposed transaction is expected to complete tentatively prior to March 31, 2026. The Board of Directors of the company, in their meeting held on November 24, 2025, has approved the same.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
